University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medical Biology
  • Medical Biology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medical Biology
  • Medical Biology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies

    Thumbnail
    Download
    published version (356.5Kb)

    Citations
    Scopus
    Web of Science
    Altmetric
    26
    21
    Author
    Weeden, CE; Solomon, B; Asselin-Labat, M-L
    Date
    2015-01-01
    Source Title
    Cell Death Discovery
    Publisher
    NATURE PUBLISHING GROUP
    University of Melbourne Author/s
    Asselin-Labat, Marie-Liesse; Solomon, Benjamin; Weeden, Clare Elizabeth
    Affiliation
    Medical Biology (W.E.H.I.)
    Medicine and Radiology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Weeden, C. E., Solomon, B. & Asselin-Labat, M. -L. (2015). FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. CELL DEATH DISCOVERY, 1 (1), https://doi.org/10.1038/cddiscovery.2015.49.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/256423
    DOI
    10.1038/cddiscovery.2015.49
    Abstract
    Although the incidence of lung cancer has decreased due to the reduction of tobacco use, lung cancer remains the leading cause of cancer-related death. Lung squamous cell carcinoma represents 30% of lung cancers and only recently have possible drug-targetable mutations been identified in this disease, including fibroblast growth factor receptor 1 (FGFR1) gene amplification and genetic alterations in the phosphoinositide-3 kinase pathway. These discoveries have generated a great interest in the clinic and the initiation of clinical trials using FGFR tyrosine kinase inhibitors to treat FGFR-altered lung cancers. However, preliminary results from these studies have shown that not all patients respond to therapy. Here we review current unresolved questions on the selection of patients for their recruitment in FGFR tyrosine kinase inhibitor trials, how FGFR inhibitors could be combined with other targeted therapies or immunotherapies to improve patient outcome, and how the current preclinical models can help address these questions.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45770]
    • Medicine and Radiology - Research Publications [2347]
    • Medical Biology - Research Publications [865]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors